ABBISKO-B(02256): The first patient has been dosed in the clinical trial of the new pan-KRAS inhibitor ABSK211.
He Yu-B (02256) announced that its subsidiary, Shanghai He Yu Biomedical Technology Co., Ltd. ("He Yu Pharmaceutical"), has completed the first patient dosing in a Phase I clinical trial of its oral, highly potent, and broadly covering small molecule pan-KRAS inhibitor ABSK211 for the treatment of patients with advanced solid tumors carrying KRAS gene alterations.
ABBISKO-B (02256) announced that its subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharma), has reported that the Phase I clinical trial of its oral, high-potency, and broadly targeted small molecule pan-KRAS inhibitor ABSK211 for the treatment of patients with advanced solid tumors carrying KRAS gene alterations has completed dosing in the first patient.
Related Articles
HK Stock Market Move | MININGLAMP-W (02718) rose over 9% in the afternoon, with revenue increasing over 18% in the first half of the year, and integrated intelligent services business growing more than sixfold.
HK Stock Market Move | Shandong Gold Mining (01787) rose over 7% in the afternoon, with its mid-term net profit attributable to the parent company increasing by 26.17% year-on-year. The company is steadily advancing its volume increase projects.
HK Stock Market Move | TIANGONG INT'L (00826) rose over 7%. In the first half of the year, excluding exchange rate effects, core net profit surged 2.4 times, with impressive performances in the high-speed steel and cutting tool businesses.
HK Stock Market Move | MININGLAMP-W (02718) rose over 9% in the afternoon, with revenue increasing over 18% in the first half of the year, and integrated intelligent services business growing more than sixfold.
HK Stock Market Move | Shandong Gold Mining (01787) rose over 7% in the afternoon, with its mid-term net profit attributable to the parent company increasing by 26.17% year-on-year. The company is steadily advancing its volume increase projects.
HK Stock Market Move | TIANGONG INT'L (00826) rose over 7%. In the first half of the year, excluding exchange rate effects, core net profit surged 2.4 times, with impressive performances in the high-speed steel and cutting tool businesses.
RECOMMEND
